Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects

Although significant improvements in standard therapy for ovarian carcinoma have been made over the past decade, current treatment is limited by the development of resistance to cytotoxic chemotherapy, and most women ultimately die of the disease. New knowledge of the biology of ovarian cancer has led to the identification of potential molecular targets that are differentially expressed in normal cells versus cancer cells, and advances in pharmacology have led to the development of novel agents that work differently from traditional cytotoxic chemotherapy by exploiting these targets. Many of these agents are being evaluated in clinical trials. This article discusses molecular targets that are important in ovarian carcinoma, including angiogenesis, tyrosine kinases, mitogen-activated protein kinases, and phosphatidylinositol-like kinases such as mammalian target of rapamycin, and the proteosome. This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Lainie Martin, MD, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19103. E-mail: L_Martin@fccc.edu
  • 1.

    JemalASiegelRWardE. Cancer statistics, 2006. CA Cancer J Clin2006;56:106130.

  • 2.

    ManningGWhyteDBMartinezR. The protein kinase complement of the human genome. Science2002;298:19121934.

  • 3.

    HunterT. Signaling—2000 and beyond. Cell2000;100:113127.

  • 4.

    Blume-JensenPHunterT. Oncogenic kinase signalling. Nature2001;411:355365.

  • 5.

    CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 6.

    ShepherdFARodrigues PereiraJCiuleanuT. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med2005;353:123132.

  • 7.

    WongSWitteON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol2004;22:247306.

  • 8.

    KantarjianHSawyersCHochhausA. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med2002;346:645652.

    • Search Google Scholar
    • Export Citation
  • 9.

    DemetriGDvon MehrenMBlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472480.

    • Search Google Scholar
    • Export Citation
  • 10.

    GorskiDHLealADGoydosJS. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg2003;197:408418.

    • Search Google Scholar
    • Export Citation
  • 11.

    KrauseSForsterYKraemerK. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and cisplatin. J Urol2005;174:328331.

    • Search Google Scholar
    • Export Citation
  • 12.

    SanbornRESandlerAB. The safety of bevacizumab. Expert Opin Drug Saf2006;5:289301.

  • 13.

    JainRK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med2001;7:987989.

  • 14.

    JainRK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science2005;307:5862.

  • 15.

    MidgleyRKerrD. Bevacizumab—current status and future directions. Ann Oncol2005;16:9991004.

  • 16.

    LeungDWCachianesGKuangWJ. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science1989;246:13061309.

  • 17.

    ToiMMatsumotoTBandoH. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol2001;2:667673.

    • Search Google Scholar
    • Export Citation
  • 18.

    YamamotoYToiMKondoS. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res1996;2:821826.

    • Search Google Scholar
    • Export Citation
  • 19.

    RaspolliniMRAmunniGVillanucciA. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer2004;14:815823.

    • Search Google Scholar
    • Export Citation
  • 20.

    NishidaNYanoHKomaiK. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer2004;101:13641374.

    • Search Google Scholar
    • Export Citation
  • 21.

    BelottiDPaganoniPManentiL. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res2003;63:52245229.

    • Search Google Scholar
    • Export Citation
  • 22.

    MonkBJChoiDCPugmireGBurgerRA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol2005;96:902905.

    • Search Google Scholar
    • Export Citation
  • 23.

    BurgerRASillMMonkBJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract]. J Clin Oncol2005;23(Suppl 1):457s. Abstract 5009.

    • Search Google Scholar
    • Export Citation
  • 24.

    GarciaAAOzaAMHirteH. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial [abstract]. J Clin Oncol2005;23(Suppl 1):455s. Abstract 5000.

    • Search Google Scholar
    • Export Citation
  • 25.

    HainsworthJDSosmanJASpigelDR. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol2005;23:78897896.

    • Search Google Scholar
    • Export Citation
  • 26.

    HerbstRSJohnsonDHMininbergE. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol2005;23:25442555.

    • Search Google Scholar
    • Export Citation
  • 27.

    DicklerMRugoHCaravelliJ. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) [abstract]. J Clin Oncol2004;22(suppl):127s. Abstract 2001.

    • Search Google Scholar
    • Export Citation
  • 28.

    DupontJRothenbergMLSpriggsDR. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors [abstract]. J Clin Oncol2005;23(suppl 1):199s. Abstract 3029.

    • Search Google Scholar
    • Export Citation
  • 29.

    HuLHofmannJHolashJ. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res2005;11(19 Pt 1):69666971.

    • Search Google Scholar
    • Export Citation
  • 30.

    Eleutherakis-PapaiakovouVBamiasADimopoulosMA. Thalidomide in cancer medicine. Ann Oncol2004;15:11511160.

  • 31.

    CraneEListA. Immunomodulatory drugs. Cancer Invest2005;23:625634.

  • 32.

    BarlogieBDesikanREddlemonP. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood2001;98:492494.

    • Search Google Scholar
    • Export Citation
  • 33.

    SinghalSMehtaJDesikanR. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med1999; 341:15651571.

  • 34.

    WeberDRankinKGavinoM. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol2003;21:1619.

  • 35.

    EisenTBoshoffCMakI. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer2000;82:812817.

    • Search Google Scholar
    • Export Citation
  • 36.

    AbramsonNStokesPKLukeM. Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide. J Clin Oncol2002;20:11471149.

    • Search Google Scholar
    • Export Citation
  • 37.

    DownsLSJrArgentaPGhebreR. A prospective randomized trial of thalidomide with topotecan compared to topotecan alone in women with recurrent epithelial ovarian primary peritoneal or fallopian tube carcinoma. Presented at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer. Palm Springs California March 22–26 2006.

    • Search Google Scholar
    • Export Citation
  • 38.

    RosenLMulayMLongJ. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract]. Proc Am Soc Clin Oncol2003;2003:191. Abstract 765.

    • Search Google Scholar
    • Export Citation
  • 39.

    ThomasALMorganBHorsfieldMA. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol2005;23:41624171.

    • Search Google Scholar
    • Export Citation
  • 40.

    SchroderWWitteveenEAbadieS. A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to IV epithelial ovarian cancer [abstract]. J Clin Oncol2005;23(Suppl 1):465s. Abstract 5042.

    • Search Google Scholar
    • Export Citation
  • 41.

    RosenLKurzrockRJacksonE. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors [abstract]. J Clin Oncol2005;23(Suppl 1):195s. Abstract 3013.

    • Search Google Scholar
    • Export Citation
  • 42.

    WedgeSRKendrewJHennequinLF. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res2005;65:4389-4400.

    • Search Google Scholar
    • Export Citation
  • 43.

    GrossMEShazerRLAgusDB. Targeting the HER-kinase axis in cancer. Semin Oncol2004;31(1 Suppl 3):920.

  • 44.

    YardenYSliwkowskiMX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol2001;2:127137.

  • 45.

    BurgessAWChoHSEigenbrotC. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell2003;12:541552.

  • 46.

    JorissenRNWalkerFPouliotN. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res2003;284:3153.

  • 47.

    BerchuckARodriguezGCKamelA. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol1991;164:669674.

    • Search Google Scholar
    • Export Citation
  • 48.

    BartlettJMLangdonSPSimpsonBJ. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer1996;73:301306.

    • Search Google Scholar
    • Export Citation
  • 49.

    Fischer-ColbrieJWittAHeinzlH. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res1997;17(1B):613619.

    • Search Google Scholar
    • Export Citation
  • 50.

    GoffBAShyKGreerBE. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynaecol Oncol1996;17:487492.

    • Search Google Scholar
    • Export Citation
  • 51.

    NicholsonRIGeeJMHarperME. EGFR and cancer prognosis. Eur J Cancer2001;37(Suppl 4):S9S15.

  • 52.

    BookmanMADarcyKMClarke-PearsonD. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol2003;21:283290.

    • Search Google Scholar
    • Export Citation
  • 53.

    AdamsCWAllisonDEFlagellaK. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother2006;55:717727.

    • Search Google Scholar
    • Export Citation
  • 54.

    AgusDBAkitaRWFoxWD. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell2002;2:127137.

  • 55.

    AgusDBGordonMSTaylorC. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol2005;23:25342543.

    • Search Google Scholar
    • Export Citation
  • 56.

    GordonMSMateiDAghajanianC. Clinical activity of pertuzumab (rhumba 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol2006; Aug 8 [Epub ahead of print].

    • Search Google Scholar
    • Export Citation
  • 57.

    NahtaRHungMCEstevaFJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res2004;64:23432346.

    • Search Google Scholar
    • Export Citation
  • 58.

    FriessTScheuerWHasmannM. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res2005;11:53005309.

    • Search Google Scholar
    • Export Citation
  • 59.

    BaselgaJPfisterDCooperMR. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol2000;18:904914.

    • Search Google Scholar
    • Export Citation
  • 60.

    del CarmenMGRizviIChangY. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst2005;97:15161524.

    • Search Google Scholar
    • Export Citation
  • 61.

    ArmstrongDKBundyBWenzelL. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med2006;354:3443.

  • 62.

    AghajanianCSabbatiniPDerosaF. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer [abstract]. J Clin Oncol2005;23(Suppl):466s. Abstract 5047.

    • Search Google Scholar
    • Export Citation
  • 63.

    GordonANFinklerNEdwardsRP. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer2005;15:785792.

    • Search Google Scholar
    • Export Citation
  • 64.

    BlankSVCurtinJPGoldmanNA. Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer [abstract]. J Clin Oncol2005;23(Suppl 1):467s. Abstract 5052.

    • Search Google Scholar
    • Export Citation
  • 65.

    VaseyPKayeSPaulJ. A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers [abstract]. J Clin Oncol2004;22(Suppl):453s. Abstract 5017.

    • Search Google Scholar
    • Export Citation
  • 66.

    SchilderRJSillMWChenX. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res2005;11:55395548.

    • Search Google Scholar
    • Export Citation
  • 67.

    BurrisHAIIIHurwitzHIDeesEC. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol2005;23:53055313.

    • Search Google Scholar
    • Export Citation
  • 68.

    VersolaMBurrisHAJonesS. Clinical activity of GW572016 in EGF10003 in patients with solid tumors [abstract]. J Clin Oncol2004;22(Suppl):206s. Abstract 3047.

    • Search Google Scholar
    • Export Citation
  • 69.

    MinamiHNakagawaKKawadaK. A phase I study of GW572016 in patients with solid tumors [abstract]. J Clin Oncol2004;22(Suppl):207s. Abstract 3048.

    • Search Google Scholar
    • Export Citation
  • 70.

    DeesECBurrisHHurwitzH. Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study [abstract]. J Clin Oncol2004; 22(Suppl):241s. Abstract 3188.

    • Search Google Scholar
    • Export Citation
  • 71.

    JonesSFHainsworthJDSpigelDR. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009) [abstract]. J Clin Oncol2004;22(Suppl):147s. Abstract 2083.

    • Search Google Scholar
    • Export Citation
  • 72.

    LenzHJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev2003;29(Suppl 1):4148.

  • 73.

    DaltonWS. The proteasome. Semin Oncol2004;31(Suppl 16):39; discussion 33.

  • 74.

    AdamsJ. The development of proteasome inhibitors as anticancer drugs. Cancer Cell2004;5:417421.

  • 75.

    AnBGoldfarbRHSimanRDouQP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ1998;5:10621075.

    • Search Google Scholar
    • Export Citation
  • 76.

    AnWGHwangSGTrepelJBBlagosklonnyMV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia2000;14:12761283.

    • Search Google Scholar
    • Export Citation
  • 77.

    DouQPMcGuireTFPengYAnB. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther1999;289:781790.

    • Search Google Scholar
    • Export Citation
  • 78.

    FrankelAManSElliottP. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res2000;6:37193728.

    • Search Google Scholar
    • Export Citation
  • 79.

    MaMHYangHHParkerK. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res2003;9:11361144.

    • Search Google Scholar
    • Export Citation
  • 80.

    OrlowskiRZStinchcombeTEMitchellBS. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol2002;20:44204427.

    • Search Google Scholar
    • Export Citation
  • 81.

    RichardsonPGBarlogieBBerensonJ. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med2003;348:26092617.

  • 82.

    AghajanianCSoignetSDizonDS. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res2002;8:25052511.

    • Search Google Scholar
    • Export Citation
  • 83.

    ApplemanLJRyanDPClarkJW. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol2003;22:209s. Abstract 839.

    • Search Google Scholar
    • Export Citation
  • 84.

    FanucchiMPBeltRJFossellaFV. Phase (ph) 2 study of bortezomib {+/–} docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): preliminary results [abstract]. J Clin Oncol2004;22(Suppl):643s. Abstract 7107.

    • Search Google Scholar
    • Export Citation
  • 85.

    VoortmanJSmitEFKuenenBC. A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: preliminary results of a phase IB study [abstract]. J Clin Oncol2005;23(Suppl 1):160s. Abstract 2103.

    • Search Google Scholar
    • Export Citation
  • 86.

    ShapiroCLRamaswamyBYoungD. Phase I trial of bortezomib in combination with paclitaxel in advanced solid tumor patients (pts) [abstract]. J Clin Oncol2005;23(Suppl 1):217s. Abstract 3104.

    • Search Google Scholar
    • Export Citation
  • 87.

    AghajanianCDizonDSSabbatiniP. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol2005;23:59435949.

    • Search Google Scholar
    • Export Citation
  • 88.

    DyGKBruzekLMCroghanGA. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res2005;11:18771883.

    • Search Google Scholar
    • Export Citation
  • 89.

    BeeramMPatnaikARowinskyEK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol2005;23:67716790.

  • 90.

    WelshSHirteHSchilderRJ. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial [abstract]. J Clin Oncol2006;24(Suppl 1):127s. Abstract 5084.

    • Search Google Scholar
    • Export Citation
  • 91.

    GaoNFlynnDCZhangZ. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol2004;287:C281C291.

    • Search Google Scholar
    • Export Citation
  • 92.

    AltomareDAWangHQSkeleKL. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene2004;23:58535857.

    • Search Google Scholar
    • Export Citation
  • 93.

    AtkinsMBHidalgoMStadlerWM. Randomized phase II study of multiple dose levels of cci-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol2004;22:909918.

    • Search Google Scholar
    • Export Citation
  • 94.

    TaberneroJRojoFBurrisH. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol2005;23(suppl 1):193s. Abstract 3007.

    • Search Google Scholar
    • Export Citation
  • 95.

    GordonANSchultesBCGallionH. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol2004;94:340351.

    • Search Google Scholar
    • Export Citation
  • 96.

    BerekJSTaylorPTGordonA. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol2004;22:35073516.

    • Search Google Scholar
    • Export Citation
  • 97.

    SchwartzGKIlsonDSaltzL. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol2001;19:19851992.

    • Search Google Scholar
    • Export Citation
  • 98.

    SenderowiczAMHeadleeDStinsonSF. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol1998;16:29862999.

    • Search Google Scholar
    • Export Citation
  • 99.

    BibleKCLensingJLNelsonSA. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res2005;11:59355941.

    • Search Google Scholar
    • Export Citation
  • 100.

    StadlerWMVogelzangNJAmatoR. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol2000;18:371375.

    • Search Google Scholar
    • Export Citation
  • 101.

    AkliluMKindlerHLDonehowerRC. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol2003;14:12701273.

  • 102.

    SchwartzGKO'ReillyEIlsonD. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol2002;20:21572170.

    • Search Google Scholar
    • Export Citation
  • 103.

    TherassePArbuckSGEisenhauerEA. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst2000;92:205216.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 47 47 5
PDF Downloads 11 11 0
EPUB Downloads 0 0 0